MD Biosciences
Established in 2006, MD Biosciences Neuro offers translational contract research services with a focus on neuropathic pain, neurodegeneration and related capabilities, including GLP-toxicology and FDA submission by SEND. Validated bespoke models in minipigs, domestic pigs, rodents, ex vivo and in vitro platforms support all aspects of in-depth non-clinical developmental needs. MDB is a signatory to the Marseille Declaration and is accredited to standards of GLP, OLAW, and AAALAC.
